Status:
COMPLETED
Therapy for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia
Lead Sponsor:
St. Jude Children's Research Hospital
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Lymphoblastic Leukemia, Acute
Eligibility:
All Genders
12-18 years
Phase:
PHASE3
Brief Summary
The primary objective is to estimate the overall event-free survival of children at least one year of age at diagnosis who are treated with risk-directed therapy and to monitor the molecular remission...
Detailed Description
These are the following secondary objectives: * To determine if CNS irradiation can be safely omitted in the context of the systemic therapy used in the protocol. * To identify whether prolonged (24 ...
Eligibility Criteria
Inclusion
- Diagnosis of non-B-cell ALL by immunophenotyping, as determined by the reactivity pattern to a panel of monoclonal antibodies with flow cytometry as well as morphology and cytochemical staining.
- Age range: 1 to 18 years (inclusive).
Exclusion
- • Previously treated with chemotherapy for one week or longer.
Key Trial Info
Start Date :
July 8 2000
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2014
Estimated Enrollment :
501 Patients enrolled
Trial Details
Trial ID
NCT00137111
Start Date
July 8 2000
End Date
April 1 2014
Last Update
September 11 2020
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
St Jude Children's Research Hospital
Memphis, Tennessee, United States, 38105
2
Cook Children's Medical Center
Fort Worth, Texas, United States, 76104